- Home
- DEA vs RXST Comparison
DEA vs RXST Comparison
Compare DEA & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- RXST
- Stock Information
- Founded
- DEA 2011
- RXST 1997
- Country
- DEA United States
- RXST United States
- Employees
- DEA N/A
- RXST N/A
- Industry
- DEA Real Estate Investment Trusts
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DEA Real Estate
- RXST Health Care
- Exchange
- DEA Nasdaq
- RXST Nasdaq
- Market Cap
- DEA 1.1B
- RXST 1.2B
- IPO Year
- DEA 2015
- RXST 2021
- Fundamental
- Price
- DEA $10.79
- RXST $29.60
- Analyst Decision
- DEA Buy
- RXST Strong Buy
- Analyst Count
- DEA 2
- RXST 8
- Target Price
- DEA $12.50
- RXST $58.13
- AVG Volume (30 Days)
- DEA 1.3M
- RXST 492.3K
- Earning Date
- DEA 02-25-2025
- RXST 02-25-2025
- Dividend Yield
- DEA 9.82%
- RXST N/A
- EPS Growth
- DEA N/A
- RXST N/A
- EPS
- DEA 0.17
- RXST N/A
- Revenue
- DEA $302,121,000.00
- RXST $128,293,000.00
- Revenue This Year
- DEA N/A
- RXST $60.30
- Revenue Next Year
- DEA $8.91
- RXST $34.65
- P/E Ratio
- DEA $63.26
- RXST N/A
- Revenue Growth
- DEA 2.98
- RXST 67.52
- 52 Week Low
- DEA $10.45
- RXST $26.29
- 52 Week High
- DEA $14.53
- RXST $66.54
- Technical
- Relative Strength Index (RSI)
- DEA 43.14
- RXST 33.54
- Support Level
- DEA $10.45
- RXST $29.65
- Resistance Level
- DEA $10.87
- RXST $32.25
- Average True Range (ATR)
- DEA 0.22
- RXST 1.25
- MACD
- DEA -0.00
- RXST -0.14
- Stochastic Oscillator
- DEA 44.67
- RXST 4.66
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.